Beta Drugs Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
BETA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts less than Nifty Microcap 250 and 0.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Beta Drugs reported consolidated revenue of Rs 396.0 crores for FY26, up 7.4% from Rs 368.8 crores in FY25. The branded oncology business delivered strong 20% growth while the Derma segment grew 34.8% and reached monthly break-even. EBITDA improved to Rs 86.9 crores with margins expanding to 22.6% from 21.1% in FY25. However, net profit declined slightly to Rs 41.5 crores (10.8% margin) from Rs 42.4 crores in FY25, primarily due to higher finance costs of Rs 15.37 crores from CCDs issued in November 2024. Without the CCD interest expense, net profit would have been Rs 48 crores at 12.5% margin. The company maintains a clean audit with unmodified opinion and continues pursuing its Vision 2030 strategy targeting over 80% contribution from high-margin businesses.
The revenue growth and EBITDA margin expansion are positive signs, but the slight decline in net profit due to financing costs from CCDs may create short-term concern. The company has guided that net profit would have been higher without the CCD interest, and conversion is due in May 2026 which should improve profitability going forward.